China Pharmaceutical University has divulged pyridoimidazole compounds acting as NLRP3 inflammasome and IL-1β (IL1B; IL-1β) inhibitors reported to be useful for the treatment of atherosclerosis, diabetes, neurodegeneration, gout, rheumatoid arthritis, chronic kidney, inflammatory bowel, and non-alcoholic fatty liver disease (NAFLD), among others.
Researchers from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, Parkinson’s disease and Alzheimer’s disease.
Viva Star Biosciences (Suzhou) Co. Ltd. has identified substituted sulfonylurea compounds acting as NLRP3 inflammasome inhibitors and reported to be useful for the treatment of cryopyrin-associated periodic syndrome, multiple sclerosis, atherosclerosis, type 2 diabetes, osteoarthritis, cancer, Alzheimer’s and Parkinson’s disease.
Research at Japan Tobacco Inc. has led to the development of 6-aminopyrazolopyrimidine compounds acting as NLRP3 inflammasome inhibitors and reported to be useful for the treatment of arteriosclerosis, gout, inflammatory bowel disease, amyotrophic lateral sclerosis, multiple sclerosis, nonalcoholic steatohepatitis (NASH), Alzheimer’s and Parkinson’s diseases.
Genentech Inc. has discovered sulfonimidamide compounds acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, autoimmune disease and cardiovascular, dermatological, respiratory, neurological, gastrointestinal and inflammatory disorders, among others.
Denali Therapeutics Inc. has disclosed NLRP3 inflammasome inhibitors reported to be useful for the treatment of stroke, gout, multiple sclerosis, Alzheimer's disease, hypertension, silicosis, graft-versus-host disease and nonalcoholic steatohepatitis (NASH).
Astrazeneca AB and Mitsubishi Tanabe Pharma Corp. have divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of liver, autoimmune and inflammatory bowel disease, inflammation, respiratory, cardiovascular and renal disorders.
